Breast Cancer

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Young black women are more likely to have aggress breast cancer subtypes than white women.

Targeted radiotherapy for breast cancer may improve overall quality of life and reduces side effects.

Studying HER2-positive breast cancer at the cellular level may yield new treatments.

Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.

Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.

Rising breast cancer rates in Japan highlights the need for clinical trials that include this population.

Nearly 1 million cancer deaths in China were the result of exposure to modifiable risk factors.

Discovery may lead to new immunotherapies for aggressive breast cancer.

Top articles of the week from Specialty Pharmacy Times.

Investigators compare long-term overall and disease-free survival rates in neoadjuvant versus adjuvant radiotherapy.

Global market for HER2-positive breast cancer to increase to $9.89 billion in 2025.

Treatment with paclitaxel or doxorubicin plus cyclophosphamide may increase the risk of metastatic breast cancer.

Breast microbiome may be harnessed to treat the development of breast cancer.

Investigational biosimilar to Herceptin is designed to treat HER2-positive early breast cancer.

Neratinib (Nerlynx) indicated to prevent breast cancer recurrence.

Neratinib, a kinase inhibitor, is indicated to follow therapy with trastuzumab to prevent breast cancer recurrence.

Biosimilar to trastuzumab (Herceptin) observed to have no clinically significant differences than the reference product.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

Biomarker status could indicate palbociclib resistance in patients with estrogen receptor-positive breast cancer.

Certain biomarkers influence outcomes in breast cancer patients treated with palbociclib.

Top articles of the week from The American Journal of Pharmacy Benefits.

Abemaciclib is a CDK4/6 inhibitor being explored in advanced breast cancer.

Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor for advanced breast cancer.

Top articles of the week from Specialty Pharmacy Times.